Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

PenkeTrading Jun. 25 at 8:06 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Soligenix Inc. Is that bullish or bearish? $SNGX #Soligenix #RsiOversold #NASDAQ

0 · Reply

HavocTradess Jun. 24 at 10:44 PM

$SNGX added some today. Expect a recovery to 1.70’s by EOW

0 · Reply

GreedyGopher Jun. 24 at 2:51 PM

$SNGX funny how over a million shares were sold prior to market open, yet there was no news to warrant this. Insiders leaving you holding the bag...... never brought anything to market... never will

0 · Reply

Matteus91 Jun. 24 at 10:53 AM

$SNGX Can someone tell me what's going on?

0 · Reply

Wannaone Jun. 24 at 10:52 AM

$SNGX I had to lose my 30% for this pos

1 · Reply

Wannaone Jun. 24 at 9:58 AM

$SNGX WTF

0 · Reply

Dreamer89 Jun. 24 at 9:56 AM

$SNGX wooohooooo bro I am basking in these pump dumps this morning 😂😂😂😂💵💵💵💵💵

0 · Reply

GreedyGopher Jun. 23 at 1:23 PM

$SNGX heading for another reverse split??? . If you are long here, you have 1/225th of the qty of shares you started out with a few yars ago...possibly soon to be 1/3,375 when this gets sub $1 yet again.. remember.. they have never brought anything to market and never will.....yet schaber makes alot of money........hmmmmmm

1 · Reply

NetworkNewsWire Jun. 18 at 6:31 PM

$SNGX Proprietary Therapy Shows Promise in Treatment of Psoriasis https://ibn.fm/VrH4V

0 · Reply

NetworkNewsWire Jun. 17 at 6:03 PM

Study Finds the Overall Prevalence of Psoriasis in the US Unchanged $SNGX https://ibn.fm/wWR7e #biomedstocks #Psoriasis

0 · Reply

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 6 weeks ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 2 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 3 months ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 3 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 4 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 5 months ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 5 months ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 5 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 6 months ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 7 months ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 7 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 7 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 8 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 8 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 8 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 9 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 9 months ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 9 months ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 9 months ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 10 months ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 11 months ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 11 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 14, 2024, 7:30 AM EDT - 1 year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Jun 7, 2024, 9:00 AM EDT - 1 year ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

STSS

May 31, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Reverse Stock Split

May 29, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 24, 2024, 7:30 AM EDT - 1 year ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 23, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 21, 2024, 7:30 AM EDT - 1 year ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 20, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 16, 2024, 7:30 AM EDT - 1 year ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 10, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

May 6, 2024, 7:30 AM EDT - 1 year ago

Soligenix to Present at Upcoming Conferences

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Soligenix Announces Pricing of $4.75 Million Public Offering

Apr 15, 2024, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Apr 11, 2024, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

Mar 15, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

Feb 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

Jan 26, 2024, 9:00 AM EST - 1 year ago

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

PenkeTrading Jun. 25 at 8:06 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Soligenix Inc. Is that bullish or bearish? $SNGX #Soligenix #RsiOversold #NASDAQ

0 · Reply

HavocTradess Jun. 24 at 10:44 PM

$SNGX added some today. Expect a recovery to 1.70’s by EOW

0 · Reply

GreedyGopher Jun. 24 at 2:51 PM

$SNGX funny how over a million shares were sold prior to market open, yet there was no news to warrant this. Insiders leaving you holding the bag...... never brought anything to market... never will

0 · Reply

Matteus91 Jun. 24 at 10:53 AM

$SNGX Can someone tell me what's going on?

0 · Reply

Wannaone Jun. 24 at 10:52 AM

$SNGX I had to lose my 30% for this pos

1 · Reply

Wannaone Jun. 24 at 9:58 AM

$SNGX WTF

0 · Reply

Dreamer89 Jun. 24 at 9:56 AM

$SNGX wooohooooo bro I am basking in these pump dumps this morning 😂😂😂😂💵💵💵💵💵

0 · Reply

GreedyGopher Jun. 23 at 1:23 PM

1 · Reply

NetworkNewsWire Jun. 18 at 6:31 PM

$SNGX Proprietary Therapy Shows Promise in Treatment of Psoriasis https://ibn.fm/VrH4V

0 · Reply

NetworkNewsWire Jun. 17 at 6:03 PM

Study Finds the Overall Prevalence of Psoriasis in the US Unchanged $SNGX https://ibn.fm/wWR7e #biomedstocks #Psoriasis

0 · Reply

NetworkNewsWire Jun. 17 at 5:06 PM

$SNGX Makes Advancement in Proprietary Treatment for Behçet’s Disease https://ibn.fm/sz8qG

0 · Reply

NetworkNewsWire Jun. 12 at 5:21 PM

InvestorNewsBreaks – $SNGX Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026 https://ibn.fm/rk4RC

0 · Reply

GreedyGopher Jun. 10 at 2:26 PM

$SNGX when is the next 1 for 15 reverse split?? cant wait!

0 · Reply

NetworkNewsWire Jun. 6 at 6:40 PM

$SNGX Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL https://ibn.fm/kzpo4

0 · Reply

NetworkNewsWire Jun. 5 at 7:11 PM

Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation $SNGX https://ibn.fm/Tdh6U #biomedstocks #cancer

0 · Reply

NetworkNewsWire Jun. 4 at 3:25 PM

BioMedNewsBreaks — $SNGX Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim https://ibn.fm/sCfYo

0 · Reply

BIGPHILLY May. 30 at 1:36 PM

$SNGX I used to trade this. Biotech is dead.

0 · Reply

Vote4Pedro2 May. 30 at 1:34 PM

$SBET $SNGX is next

0 · Reply

Vote4Pedro2 May. 29 at 8:42 PM

$SBET good job $SNGX is next t o pop

0 · Reply

Vote4Pedro2 May. 29 at 4:12 PM

$SNGX Any new news

0 · Reply

NetworkNewsWire May. 27 at 6:56 PM

New Swallowable Pill Provides Real-Time Gut Inflammation Tracking $SNGX https://ibn.fm/Zgkio #biomedstocks #Inflammation

0 · Reply

NetworkNewsWire May. 23 at 4:56 PM

$SNGX Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics https://ibn.fm/zdBFA

0 · Reply

Market Cap	4.41M
Revenue (ttm)	120,000.00
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,891.67%
Debt to Equity Ratio	0.00

Volume	97,600
Avg Vol	69,826
Day's Range	N/A - N/A
Shares Out	3.26M
Stochastic %K	11%
Beta	1.97
Analysts	Strong Buy
Price Target	$22.50